Compare PANW & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANW | REGN |
|---|---|---|
| Founded | 2005 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.7B | 73.9B |
| IPO Year | 2012 | 1991 |
| Metric | PANW | REGN |
|---|---|---|
| Price | $186.91 | $765.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 40 | 23 |
| Target Price | $224.00 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 6.8M | 1.1M |
| Earning Date | 11-19-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 0.46% |
| EPS Growth | N/A | ★ 2.88 |
| EPS | 1.58 | ★ 41.59 |
| Revenue | $9,556,500,000.00 | ★ $14,247,800,000.00 |
| Revenue This Year | $16.46 | $1.95 |
| Revenue Next Year | $13.25 | $5.47 |
| P/E Ratio | $118.28 | ★ $18.46 |
| Revenue Growth | ★ 15.30 | 2.89 |
| 52 Week Low | $144.15 | $476.49 |
| 52 Week High | $223.61 | $790.98 |
| Indicator | PANW | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 64.36 |
| Support Level | $183.19 | $739.23 |
| Resistance Level | $188.33 | $757.35 |
| Average True Range (ATR) | 4.34 | 19.21 |
| MACD | -0.04 | -1.25 |
| Stochastic Oscillator | 23.70 | 98.42 |
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).